Alzheimer's Disease (AD) remains one of the most challenging and devastating neurodegenerative diseases affecting millions of individuals worldwide. Characterized by progressive cognitive decline, memory loss and eventual impairment in daily activities, AD poses a significant burden on patients, caregivers and healthcare systems. While much research has been devoted to understanding the underlying mechanisms of AD, effective therapeutic interventions that halt or reverse its progression remain elusive. Among the pathological hallmarks of AD are the accumulation of beta-amyloid plaques and the formation of Neurofibrillary Tangles (NFTs) primarily composed of hyperphosphorylated tau protein. While amyloidbeta targeting strategies have been a major focus of drug development, recent attention has shifted towards emerging therapeutic approaches targeting tau pathology.
HTML PDFShare this article
